» Articles » PMID: 23935815

The Age-specific Quantitative Effects of Metabolic Risk Factors on Cardiovascular Diseases and Diabetes: a Pooled Analysis

Abstract

Background: The effects of systolic blood pressure (SBP), serum total cholesterol (TC), fasting plasma glucose (FPG), and body mass index (BMI) on the risk of cardiovascular diseases (CVD) have been established in epidemiological studies, but consistent estimates of effect sizes by age and sex are not available.

Methods: We reviewed large cohort pooling projects, evaluating effects of baseline or usual exposure to metabolic risks on ischemic heart disease (IHD), hypertensive heart disease (HHD), stroke, diabetes, and, as relevant selected other CVDs, after adjusting for important confounders. We pooled all data to estimate relative risks (RRs) for each risk factor and examined effect modification by age or other factors, using random effects models.

Results: Across all risk factors, an average of 123 cohorts provided data on 1.4 million individuals and 52,000 CVD events. Each metabolic risk factor was robustly related to CVD. At the baseline age of 55-64 years, the RR for 10 mmHg higher SBP was largest for HHD (2.16; 95% CI 2.09-2.24), followed by effects on both stroke subtypes (1.66; 1.39-1.98 for hemorrhagic stroke and 1.63; 1.57-1.69 for ischemic stroke). In the same age group, RRs for 1 mmol/L higher TC were 1.44 (1.29-1.61) for IHD and 1.20 (1.15-1.25) for ischemic stroke. The RRs for 5 kg/m(2) higher BMI for ages 55-64 ranged from 2.32 (2.04-2.63) for diabetes, to 1.44 (1.40-1.48) for IHD. For 1 mmol/L higher FPG, RRs in this age group were 1.18 (1.08-1.29) for IHD and 1.14 (1.01-1.29) for total stroke. For all risk factors, proportional effects declined with age, were generally consistent by sex, and differed by region in only a few age groups for certain risk factor-disease pairs.

Conclusion: Our results provide robust, comparable and precise estimates of the effects of major metabolic risk factors on CVD and diabetes by age group.

Citing Articles

The Role of TLRs in Obesity and Its Related Metabolic Disorders.

Campos-Bayardo T, Roman-Rojas D, Garcia-Sanchez A, Cardona-Munoz E, Sanchez-Lozano D, Totsuka-Sutto S Int J Mol Sci. 2025; 26(5).

PMID: 40076851 PMC: 11900219. DOI: 10.3390/ijms26052229.


Burden of disease attributable to high body mass index in Belgium: a comparative risk assessment analysis.

Gorasso V, Vandevijvere S, Nusselder W, De Pauw R, Hilderink H, Nayani S BMJ Public Health. 2025; 3(1):e002446.

PMID: 40017950 PMC: 11812905. DOI: 10.1136/bmjph-2024-002446.


Comparative analysis of metabolic and bariatric surgery outcomes and complications in patients under and over 50 years of age.

Rezapanah A, Ebrahimi P, Sherafati H, Dalili A, Jangjoo A, Emadzadeh M Langenbecks Arch Surg. 2025; 410(1):71.

PMID: 39953178 PMC: 11828828. DOI: 10.1007/s00423-025-03644-5.


Development and validation of a predictive model for carotid atherosclerosis in postmenopausal women.

Liu J, Zeng X, Ruan J, Kang Y, Lu Y, Li S Sci Rep. 2025; 15(1):5079.

PMID: 39934244 PMC: 11814320. DOI: 10.1038/s41598-025-89098-7.


Associations of four obesity indices with diabetes mellitus in Korean middle-aged and older adults using the Korean Genome and Epidemiology Study (KoGES).

Lee Y, Lim N, Park H BMC Public Health. 2025; 25(1):473.

PMID: 39910521 PMC: 11800455. DOI: 10.1186/s12889-025-21567-0.


References
1.
Law M, Thompson S, Wald N . Assessing possible hazards of reducing serum cholesterol. BMJ. 1994; 308(6925):373-9. PMC: 2539477. DOI: 10.1136/bmj.308.6925.373. View

2.
Rodriguez B, Labarthe D, Huang B, Lopez-Gomez J . Rise of blood pressure with age. New evidence of population differences. Hypertension. 1994; 24(6):779-85. DOI: 10.1161/01.hyp.24.6.779. View

3.
Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A . Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003; 32(4):563-72. DOI: 10.1093/ije/dyg106. View

4.
Law M, Morris J, Wald N . Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338:b1665. PMC: 2684577. DOI: 10.1136/bmj.b1665. View

5.
Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267-78. DOI: 10.1016/S0140-6736(05)67394-1. View